OBJECTIVES: The therapeutic options for Multiple Sclerosis(MS) improved over the past years with the approval of new substances. Therapeutic optimization must take into account an individualized assessment of clinical and imaging disease activity, treatment response as well as identifying early risk factors for treatment failure. This study will address by assess this issue by 1.     Assess the utility of a tool that helps to identify patients with ongoing disease activity 2.     The systematic collection of a broader set of functional domains to explore their potential to be used as a predictive measure of future disease activity or treatment response. 3.     Evaluate the clinical course of patients according to NEDA-4 parameter as measured by relapse activity, disability progression, MRI activity and change in brain volume. 4.     Assess the therapeutic effectiveness of switching to fingolimod if the patients are assessed to be failing their current first line therapy. METHODS: